We are the Leaders in Immuno-Oncology & Liquid Biopsy Testing.

Clinical Relevance of Genomics in Cancer Medicine

  • Genomic assays that enable the characterization of the somatic and germline defects in individual tumour samples are increasingly being used in clinical diagnostics as a means of identifying therapeutic options.


  • Genomic methods can reveal individual targetable alterations, mutational load, complex mutation signatures, and tumour-specific antigens, which might inform the utilization of targeted therapies, immune-checkpoint inhibitors, and personalized anticancer vaccines.


  • The occurrence of shared targetable alterations across diverse tumour types has prompted new paradigms in the application of genomic profiling and the design of clinical trials.


These Assays Increasingly Provide Information 

That is Pertinent to Clinical Cancer Care. 


Review Glossary of FDA Approved Targeted Drugs

We Offer Niche Tests & Technologies

Liquid Biopsy

Circulating Tumor DNA (ctDNA)

Circulating Tumor Cell Detection (CTC)



Our Liquid Biopsy services can assist your patients in:

  • Performing tumor profiling
  • Surveillance of tumors and their response to therapy 
  • Monitor heterogeneity
  • Testing for minimal residual disease (MRD)
  • Helping predict early relapse

Testing using Peripheral Blood based liquid biopsies is more sensitive than other diagnostic testing methods like bone marrow taps, which are invasive and painful for patients.


Peripheral Blood based Tumor DNA Detection Tests are available for:


Contact Us to order a liquid Biopsy Test. medical diagnostic service blood test for cancer nsclc

Immuno Oncology

Solid Tumors

Leukemia's and Lymphoma



Immuno-Oncology (I-O) is the investigation of innovative approaches that aim to harness the body’s natural immune response to fight cancer. 

Immuno-Oncology testing helps determine which patients are good candidates for immunotherapy. Star Bioscience Laboratories is a leader in precision diagnostics and is at the forefront of immunotherapy testing.


Tumor Mutation Burden (TMB): This genomic biomarker is designed to predict response to checkpoint inhibitor immunotherapies targeting the PD-1 and PD-L1 proteins. Studies in lung, melanoma and bladder cancers showed that objective response to checkpoint immunotherapy was predicted by the presence of high TMB.


Microsatellite Instability (MSI) and Mismatch Repair (MMR): KEYTRUDA® was approved by the FDA for the treatment of certain patients with metastatic solid tumors that have been identified as being MSI-high or mismatch repair deficient (dMMR)1. OPDIVO® is FDA-approved for certain colorectal cancer patients with MSI-high or dMMR2.


PD-L1: This immunohistochemical assay detects the level and expression sites of PD-L1 protein. As a companion or complementary diagnostic for certain tumors and indications, it helps identify patients for treatments including KEYTRUDA, OPDIVO, TECENTRIQ® and IMFINZI™.


Contact Us to order an IO Test.

Multi - Gene Testing

Star Bioscenices has developed Next Generation Sequencing (NGS) testing for all cancers. 


Our approach is to serve your patients with affordable Cancer Specific - Next Generation Sequencing Multi-Gene Panels which screen 10, 50 to > 400 genes in All Solid Tumors, including:

Tests Reports include analysis from  DNA, RNA sequencing along with Pharmacogenomics.


Contact Us to order a NGS Test.

Fluorescence in situ hybridization (FISH)

Fluorescence in situ hybridization (FISH) can help identify subtle or sub-microscopic structural rearrangements, variant chromosomes, and low-frequency abnormalities not readily detectable by classic cytogenetics. 


FISH incorporates three technologies – cytogenetics, DNA hybridization, and fluorescent microscopy – to provide a uniquely informative combination of resolution and breadth. 


FISH is also called Molecular Cytogenetics.

Star Biosciences provides our clients a full menu of panels and probes with flexible ordering options to enable rapid and cost-effective characterization of solid tumors like Lung Cancer and Breast Cancer, leukemias, lymphomas, and myeloid disorders.


Contact Us to order a FISH Test.

Immunohistochemistry (IHC)

Immunohistochemistry (IHC) is a core cancer diagnostics testing method that is playing an increasingly important role in precision medicine. 


It combines immunological and biochemical techniques to identify specific components of a tissue. IHC uses a building-block system of antibodies, conjugates, and chromogens (color reagents) for detection. 


A significant advantage of IHC over other methods is that IHC allows the distribution and density of components to be visualized in relation to each other and to the rest of the tissue sample. 


Contact Us to order a IHC Test.

Molecular Tests & Heme Onc

We makes it easy for hemepaths and hem/oncs to solve medical problems in two main ways. 


  1. First, our menu allows physicians to choose the level of detail and investigation each patient requires for diagnosis, prognosis, and/or therapy selection. From simple orders for standard guideline-recommended markers to multi-parameter assays incorporating novel discoveries, 
  2. Star Biosciences provides clear, cost-effective, and efficient testing solutions that fit today’s needs.

These are some of the most frequently ordered heme tests on our menu.

  • Molecular Testing - individual Markers and Panels 
  • Cytogenetics
  • Flow-Cytometry

Contact Us to order a Molecular or Heme-Onc Test.

Contact Us

Drop us a Line & We will Contact You

India:
Contact Customer Service Representatives @
Tel: 9794048252

SE-Asia:

Drop us a line and our Customer Service will contact you. 


Africa:

Drop us a line and our Customer Service will contact you. 

FDA Approved Precision Drugs - Solid Tumors

DRUGS FOR SOLID TUMORS  

Ado-trastuzumab emtansine (Kadcyla) 

  • Target: EGFR (HER1/ERBB1), HER2 (ERBB2/neu)
  • FDA Approved Indication: 
    • Non-small cell lung cancer (with EGFR exon 19 deletions or exon 21 substitution (L858R) mutations)

    Aldesleukin (Proleukin) 

  • Target: PD-L1
  • FDA Approved Indication: 
    • Urothelial carcinoma
    • Non-small cell lung cancer

    Avelumab (Bavencio)

  • Target: PD-L1
  • FDA Approved Indication:
    • Merkel cell carcinoma
    • Urothelial cancer

    Axitinib (Inlyta)

  • Target: KIT, PDGFRβ, VEGFR1/2/3
  • FDA Approved Indication: 
    • Renal cell carcinoma

    Belimumab (Benlysta)

  • Target: VEGF ligand
  • FDA Approved Indications: 
    • Cervical cancer
    • Colorectal cancer
    • Fallopian tube cancer
    • Glioblastoma
    • Non-small cell lung cancer
    • Ovarian cancer
    • Peritoneal cancer
    • Renal cell carcinoma

    Bosutinib (Bosulif) 

  • Target: FLT3, KIT, MET, RET, VEGFR2
  • FDA Approved Indication: 
    • Medullary thyroid cancer 
    • Renal cell carcinoma

    Ceritinib (Zykadia)

  • Target: ALK
  • FDA Approved Indication: 
    • Non-small cell lung cancer (with ALK fusion)

    Cetuximab (Erbitux)

  • Target: EGFR (HER1/ERBB1)
  • FDA Approved Indication: 
    • Colorectal cancer (KRAS wild type), 
    • Squamous cell cancer of the head and neck

    Cobimetinib (Cotellic)

  • Target: ALK, MET, ROS1
  • FDA Approved Indication: 
    • Non-small cell lung cancer (with ALK fusion or ROS1 genealteration)

    Dabrafenib (Tafinlar)

  • Target: B4GALNT1 (GD2)
  • FDA Approved Indication: Pediatric neuroblastoma

Durvalumab (Imfinzi)

  • Target: PD-L1
  • FDA Approved Indication: 
    • Urothelial carcinoma
    • Non-small cell lung cancer

    Enasidenib (Idhifa)

  • Target: EGFR (HER1/ERBB1)
  • FDA Approved Indication: 
    • Non-small cell lung cancer (with EGFR exon 19 deletions or exon 21 substitution (L858R) mutations)
    • Pancreatic cancer

    Everolimus (Afinitor)

  • Target: mTOR
  • FDA Approved Indication: 
    • Pancreatic, gastrointestinal, or lung origin neuroendocrine tumor
    • Renal cell carcinoma
    • Nonresectable subependymal giant cell astrocytoma associated with tuberous sclerosis
    • Breast cancer (HR+, HER2-)

    Gefitinib (Iressa)

  • Target: EGFR (HER1/ERBB1)
  • FDA Approved Indication: 
    • Non-small cell lung cancer (with EGFR exon 19 deletions or exon 21 substitution (L858R) mutations)

    Ibrutinib (Imbruvica)

  • Target: BTK
  • FDA Approved Indication: 
    • Mantle cell lymphoma
    • Chronic lymphocytic leukemia
    • Waldenstrom's macroglobulinemia

    Idelalisib (Zydelig)

  • Target: PI3Kδ
  • FDA Approved Indication: 
    • Chronic lymphocytic leukemia
    • Follicular B-cell non-Hodgkin lymphoma
    • Small lymphocytic lymphoma

    Imatinib (Gleevec)

  • Target: KIT, PDGFR, ABL
  • FDA Approved Indication: 
    • GI stromal tumor (KIT+)
    • Dermatofibrosarcoma protuberans
    • Multiple hematologic malignancies including Philadelphia chromosome-positive ALL and CML

    Ipilimumab (Yervoy)

  • Target: CTLA-4
  • FDA Approved Indication: 
    • Melanoma
    • Renal cell carcinoma

    Ixazomib (Ninlaro)

  • Target: Proteasome
  • FDA Approved Indication: Multiple Myeloma

Lapatinib (Tykerb)

  • Target: HER2 (ERBB2/neu), EGFR (HER1/ERBB1)
  • FDA Approved Indication: 
    • Breast cancer (HER2+)

    Lenvatinib (Lenvima)

  • Target: VEGFR2
  • FDA Approved Indication: 
    • Renal cell carcinoma
    • Thyroid cancer

    Midostaurin (Rydapt)

  • Target: EGFR (HER1/ERBB1)
  • FDA Approved Indication: 
    • Squamous non-small cell lung cancer

    Neratinib (Nerlynx)

  • Target: HER2 (ERBB2/neu)
  • FDA Approved Indication: 
    • Breast cancer (HER2 overexpressed/amplified)

    Niraparib (Zejula)

  • Target: PARP
  • FDA Approved Indication: 
    • Ovarian cancer​
    • Fallopian tube cancer​
    • Peritoneal cancer​

    Nivolumab (Opdivo)

  • Target: PD-1
  • FDA Approved Indication: 
    • Colorectal cancer (dMMR and MSI-H)
    • Head and neck squamous cell carcinoma
    • Hepatocellular carcinoma
    • Hodgkin lymphoma
    • Melanoma
    • Non-small cell lung cancer
    • Renal cell carcinoma
    • Urothelial carcinoma

    Olaparib (Lynparza)

  • Target: PD-1
  • FDA Approved Indication: 
    • Classical Hodgkin lymphoma
    • Colorectal cancer (MSI-H/dMMR)
    • Gastric cancer
    • Melanoma
    • Non-small cell lung cancer (PD-L1+)
    • Head and neck squamous cell carcinoma
    • Urothelial cancer
    • Solid tumors (MSI-H/dMMR)

    Pertuzumab (Perjeta)

  • Target: VEGFR2
  • FDA Approved Indications: 
    • Colorectal cancer
    • Gastric cancer or Gastroesophageal junction (GEJ) adenocarcinoma
    • Non-small cell lung cancer

    Regorafenib (Stivarga)

  • Target: KIT, PDGFRβ, RAF, RET, VEGFR1/2/3
  • FDA Approved Indications:
    • Colorectal cancer
    • Gastrointestinal stromal tumors
    • Hepatocellular carcinoma

    Ribociclib (Kisqali)

  • Target: VEGFR, PDGFR, KIT, RAF
  • FDA Approved Indication: 
    • Hepatocellular carcinoma 
    • Renal cell carcinoma 
    • Thyroid carcinoma

    Temsirolimus (Torisel)

  • Target: HER2 (ERBB2/neu)
  • FDA Approved Indication: 
    • Breast cancer (HER2+) 
    • Gastric cancer (HER2+)

    Vandetanib (Caprelsa)

  • Target: EGFR (HER1/ERBB1), RET, VEGFR2
  • FDA Approved Indication: 
    • Medullary thyroid cancer

    Vemurafenib (Zelboraf)

  • Target: PIGF, VEGFA/B
  • FDA Approved Indication: 
    • Colorectal cancer

DRUGS FOR LEUKEMIA AND LYMPHOMA 

Rituximab (Rituxan, Mabthera)

  • Target:CD20
  • FDA Approved Indications: 
    • Chronic lymphocytic leukemia
    • Diffuse large B-cell lymphoma
    • Follicular lymphoma

    Romidepsin (Istodax)

  • Target: HDAC
  • FDA Approved Indication: 
    • Cutaneous T-cell lymphoma
    • Peripheral T-cell lymphoma

    Belinostat (Beleodaq)

  • Target: CD19/CD3
  • FDA Approved Indication: 
    • Acute lymphoblastic leukemia (precursor B-cell)

    Nilotinib (Tasigna)

  • Target: CD20
  • FDA Approved Indication: 
    • Chronic lymphocytic leukemia
    • Follicular lymphoma

    Dasatinib (Sprycel)

  • Target: BCL2
  • FDA Approved Indication: 
    • Chronic lymphocytic leukemia (with 17p deletion)

    Vorinostat (Zolinza)

  • TARGET: CD52
  • FDA Approved Indication: 
    • B-cell chronic lymphocytic leukemia

    Ponatinib (Iclusig)

  • Target: ABL, FGFR1-3, FLT3, VEGFR2
  • FDA Approved Indication: 
    • Chronic myelogenous leukemia
    • Acute lymphoblastic leukemia (Philadelphia chromosome positive)

    Panobinostat (Farydak)

  • Target: HDAC
  • FDA Approved Indication: 
    • Multiple myeloma

    Elotuzumab (Empliciti)

  • Target: CD20
  • FDA Approved Indication: 
    • Non-Hodgkin's lymphoma